"Cook has clearly established itself as the world leader in developing advanced endovascular technologies to treat aortic aneurysms and dissections, and this suit seeks to protect that position from damages caused by Endologix's infringement of U.S. Patents No. 5,755,777 and No. 5,035,706," said Cook general counsel Cynthia Kretz. "As part of our vigorous defense of our patent portfolio in this area, Cook has asked the U.S. District Court to enjoin Endologix from selling all products infringing on these patents and to award Cook damages adequate to compensate for the infringement, including interest and costs."
The suit was filed Tuesday, October 6 and asks that a jury trial be held to determine the outcome of the complaint. The two patents in question are critical for Cook's leadership in the EVAR field.
The '777 Patent protects Cook's technology for its "Expandable Transluminal Graft Prosthesis for Repair of Aneurysms," and was awarded on May 26, 1998. The '706 Patent covers Cook's "Percutaneous Stent and Method of Retrieval Thereof," and was granted on July 30, 1991.
About Cook Medical
Founded in 1963, Cook Medical helped invent and popularize interventional medicine, pioneering many of the devices now commonly used worldwide to perform minimally invasive medical procedures throughout the body. Today, the company integrates minimally invasive medical devices, drugs and biologics to enhance patient safety and improve clinical outcomes. Since its inception, Cook has operated as a family-held private corporation focused on providing superior patient outcomes while reducing health care costs. For more information, visit www.cookmedical.com. You may sign up to follow Cook Medical on Twitter at twitter.com/cookmedicalpr.
SOURCE: Cook Medical
Cook Medical David McCarty, 812-339-2235, ext. 2387 or 812-322-1805 (cell) Global Director of Public Relations dave.mccarty@cookmedical.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index